Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2018

View Archived Issues

Mallinckrodt completes rolling submission of NDA for stannsoporfin

BioCryst Pharmaceuticals begins IND-enabling studies of two lead candidates

Jiangsu Chia Tai Tianqing Pharmaceutical Group and others patent JAK2 inhibitors

KalVista Pharmaceuticals initiates two clinical studies of plasma kallikrein inhibitors

F1 Oncology announces milestone in development of CCT301-38 AXL and CCT301-59 ROR2

Galapagos reports topline results from phase Ib study of GLPG-1972 in osteoarthritis

Ultragenyx reports first cohort data from phase I/II study of DTX-301 to treat OTC deficiency

Sperm cell-driven approach for targeted drug delivery in gynecological malignancies

Exelixis and StemSynergy enter into exclusive licensing agreement

Alcyone enters collaboration to improve intrathecal delivery of drugs for rare CNS disorders

FDA accepts Merck & Co.'s NDAs for doravirine

Cas9-Tmc1-mut3 RNP genome editing agent shows promise in model of autosomal dominant hearing loss

Virus-like particle vaccine targeting xCT active in breast cancer models

Novel TrpC5 ion channel inhibitor shows promise in models of progressive kidney disease

Cleveland Clinic Foundation creates novel anti-CD6 antibodies

Denali Therapeutics identifies new LRRK2 inhibitors

Preliminary results from part 1 of phase II trial of ACE-083 in patients with FSHD

New PTP-2C inhibitors synthesized at Novartis

bluebird bio describes novel TPP1 gene therapy

AbbVie's upadacitinib awarded FDA breakthrough therapy designation for atopic dermatitis

China FDA accepts IND for Ascentage's IAP inhibitor

BeiGene licenses rights to Mirati's sitravatinib

Ablynx believes Novo Nordisk's proposal to acquire Ablynx undervalues company

ProQR collaborates with Galapagos on fibrosis programs

Dynavax makes Heplisav-B available in U.S.

Grant supports Sabin Vaccine Institute's focus on next-generation influenza vaccines

First efficacy endpoint met in phase II trial of bemcentinib in NSCLC

Regeneron and Sanofi to expand investment in cemiplimab and dupilumab programs

Pivotal study of eptinezumab for migraine prevention meets key endpoints

FDA accepts Ionis' inotersen NDA for priority review

REGENXBIO and AveXis amend licensing agreement for spinal muscular atrophy products

New phase II clinical data presented for radioiodinated tositumomab in NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...